ONCR - Oncorus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1140
-0.0673 (-37.12%)
At close: 04:00PM EDT
0.1134 -0.00 (-0.53%)
After hours: 07:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1813
Open0.1123
Bid0.1100 x 800
Ask0.1100 x 1000
Day's Range0.1006 - 0.1224
52 Week Range0.1006 - 1.9000
Volume6,253,769
Avg. Volume380,293
Market Cap2.975M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ONCR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Oncorus Announces Workforce Reduction Plan

    ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55

  • GlobeNewswire

    Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

    IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneeri

  • GlobeNewswire

    Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

    Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support self-amplifying RNA platform and promise of repeat IV-administrationEnded the quarter with $62.2 million in cash, cash equivalents and investments to support next-generation RNA therapeutics pipeline ANDOVER, Mass., March 24, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines compan

  • GlobeNewswire

    Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

    Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and D

  • GlobeNewswire

    Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

    Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company’s cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, In

  • GlobeNewswire

    Oncorus to Participate in Upcoming Investor Conferences

    ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences: Evercore ISI 5th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.Piper Sandler 34th Annual Healthcare Conference

  • GlobeNewswire

    Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

    ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 expresses four immunomodulatory payloads, including IL-12, an anti-PD-1 nanobody, 15-hydroxyprostaglandin dehydrogenase (HPGD), and a novel macrophage-modulating Fc-enhanced antibody to reverse GBM’s immunosu

  • GlobeNewswire

    Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

    Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022On track to submit IND for ONCR-021 in mid-2023Completed construction phase of GMP-compliant manufacturing facility in Andover, MAEnded the quarter with $81.5 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies comp

  • GlobeNewswire

    Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

    New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients, today announced the publication of preclinical data in Nature Communications highlighting the potential of its synthetic viral RNA (vRNA)/lipid nanoparticle (LNP) platform as a nov

  • GlobeNewswire

    Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference

    ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY. A live webcast of the fireside chat can be accessed by visiting the

  • GlobeNewswire

    Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:00 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed

  • GlobeNewswire

    Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates

    Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track to submit IND for ONCR-021 in mid-2023Ended quarter with $100.2 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients,

  • GlobeNewswire

    Oncorus Appoints Douglas Fambrough to Board of Directors

    -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. “We are thrilled to welcome Doug to our board and leverage his significant expertise and executive lea